NASDAQ:INVA - Innoviva Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $10.00
  • Forecasted Upside: -9.67 %
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.07
▼ -0.15 (-1.34%)
1 month | 3 months | 12 months
Get New Innoviva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.00
▼ -9.67% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Innoviva in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a -9.67% upside from the last price of $11.07.
Sell
The current consensus among 1 contributing investment analysts is to sell stock in Innoviva. This rating has held steady since June 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2020Morgan StanleyBoost Price TargetUnderweight$8.00 ➝ $10.00Medium
i
6/25/2018Stifel NicolausReiterated RatingHold ➝ Hold$16.00High
i
4/27/2018Stifel NicolausLower Price TargetHold ➝ Hold$17.00 ➝ $16.00Medium
i
4/19/2018Berenberg BankInitiated CoverageBuyLow
i
2/9/2018Stifel NicolausReiterated RatingHold$17.00High
i
11/20/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$13.00N/A
i
10/24/2017Robert W. BairdReiterated RatingHold$13.00N/A
i
10/23/2017CowenSet Price TargetBuy$16.00N/A
i
Rating by Ken Cacciatore at Cowen Inc
10/6/2017Morgan StanleyReiterated RatingUnderweight$7.00 ➝ $8.00N/A
i
9/15/2017Stifel NicolausReiterated RatingHold ➝ NeutralLow
i
7/28/2017CowenSet Price TargetBuy$16.00Medium
i
Rating by Tyler Van Buren at Cowen Inc
7/28/2017Stifel NicolausReiterated RatingHold$15.00Medium
i
7/27/2017Robert W. BairdReiterated RatingNeutral$11.00 ➝ $13.00Medium
i
5/1/2017CowenSet Price TargetBuy$16.00Low
i
Rating by Tyler Van Buren at Cowen Inc
3/30/2017CowenBoost Price TargetOutperform$15.00 ➝ $16.00Low
i
3/14/2017Robert W. BairdReiterated RatingNeutral$11.00Medium
i
10/31/2016CowenUpgradeMarket Perform ➝ Outperform$15.00N/A
i
7/31/2016Robert W. BairdReiterated RatingNeutral$9.00 ➝ $11.00N/A
i
5/2/2016Morgan StanleyReiterated RatingSell$7.00N/A
i
(Data available from 3/4/2016 forward)
Innoviva logo
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Read More

Today's Range

Now: $11.07
$11.05
$11.22

50 Day Range

MA: $12.15
$11.22
$12.87

52 Week Range

Now: $11.07
$7.58
$15.62

Volume

358,575 shs

Average Volume

561,859 shs

Market Capitalization

$1.12 billion

P/E Ratio

5.65

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Innoviva?

The following sell-side analysts have issued reports on Innoviva in the last twelve months: Morgan Stanley, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for INVA.

What is the current price target for Innoviva?

1 Wall Street analysts have set twelve-month price targets for Innoviva in the last year. Their average twelve-month price target is $10.00, suggesting a possible downside of 9.7%. Morgan Stanley has the highest price target set, predicting INVA will reach $10.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $10.00 for Innoviva in the next year.
View the latest price targets for INVA.

What is the current consensus analyst rating for Innoviva?

Innoviva currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe INVA will underperform the market and that investors should sell shares of Innoviva.
View the latest ratings for INVA.

What other companies compete with Innoviva?

How do I contact Innoviva's investor relations team?

Innoviva's physical mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company's listed phone number is 650-238-9600 and its investor relations email address is [email protected] The official website for Innoviva is www.inva.com.